Mimedx Group Inc Financials
Mimedx Group Inc (MDXG) reported $418.6M in revenue for fiscal year 2025, up 20.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MiMedx’s model is a high-gross-margin business where cash conversion and overhead control now drive economics.
In FY2024 and FY2025, operating cash flow exceeded net income, so recent profit is showing up as real liquidity rather than staying trapped in accruals. That cash conversion coincided with cash reaching$166.1M while long-term debt fell to$16.5M , a balance-sheet shift that shows the turnaround is being funded internally.
A gross margin around
FY2024 posted higher operating income than FY2023—
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Mimedx Group Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Mimedx Group Inc has an operating margin of 15.3%, meaning the company retains $15 of operating profit per $100 of revenue. This strong profitability earns a score of 65/100, reflecting efficient cost management and pricing power. This is down from 16.9% the prior year.
Mimedx Group Inc's revenue surged 20.0% year-over-year to $418.6M, reflecting rapid business expansion. This strong growth earns a score of 73/100.
Mimedx Group Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.32, Mimedx Group Inc holds $4.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
Mimedx Group Inc earns a strong 18.9% return on equity (ROE), meaning it generates $19 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 71/100. This is down from 22.0% the prior year.
Mimedx Group Inc scores 6.81, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($631.1M) relative to total liabilities ($86.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Mimedx Group Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Mimedx Group Inc generates $1.52 in operating cash flow ($74.0M OCF vs $48.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Mimedx Group Inc earns $35.83 in operating income for every $1 of interest expense ($63.9M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Mimedx Group Inc generated $418.6M in revenue in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Mimedx Group Inc's EBITDA was $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.4% from the prior year.
Mimedx Group Inc reported $48.6M in net income in fiscal year 2025. This represents an increase of 14.5% from the prior year.
Mimedx Group Inc earned $0.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.3% from the prior year.
Cash & Balance Sheet
Mimedx Group Inc held $166.1M in cash against $16.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Mimedx Group Inc's gross margin was 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.
Mimedx Group Inc's operating margin was 15.3% in fiscal year 2025, reflecting core business profitability. This is down 1.6 percentage points from the prior year.
Mimedx Group Inc's net profit margin was 11.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.6 percentage points from the prior year.
Mimedx Group Inc's ROE was 18.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.0 percentage points from the prior year.
Capital Allocation
Mimedx Group Inc invested $15.1M in research and development in fiscal year 2025. This represents an increase of 22.3% from the prior year.
Mimedx Group Inc repurchased no shares in fiscal year 2025.
Not reported for fiscal year 2025.
MDXG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $355.2M | $418.6M+20.0% | $348.9M+8.5% | $321.5M+20.0% | $267.8M+10.7% | $242.0M-2.5% | $248.2M-17.0% | $299.3M-16.7% | $359.1M+11.8% | $321.1M+44.8% | $221.7M+18.4% | $187.3M+58.4% | $118.2M+99.8% | $59.2M+118.8% | $27.1M+248.6% | $7.8M |
| Cost of Revenue | $75.1M | $73.0M+21.5% | $60.1M+10.0% | $54.6M+13.1% | $48.3M+21.9% | $39.6M+0.8% | $39.3M-8.7% | $43.1M+18.4% | $36.4M+3.3% | $35.2M+13.8% | $30.9M+53.1% | $20.2M+59.5% | $12.7M+35.8% | $9.3M+79.8% | $5.2M+54.5% | $3.4M |
| Gross Profit | $280.1M | $345.6M+19.7% | $288.8M+8.2% | $266.8M+21.6% | $219.5M+8.5% | $202.4M-3.1% | $208.9M-18.5% | $256.2M-20.6% | $322.7M+12.9% | $285.9M+49.9% | $190.8M+14.2% | $167.1M+58.3% | $105.6M+111.7% | $49.9M+128.0% | $21.9M+396.6% | $4.4M |
| R&D Expenses | $15.4M | $15.1M+22.3% | $12.3M-2.6% | $12.7M-0.3% | $12.7M+27.9% | $9.9M-15.2% | $11.7M+5.2% | $11.1M-29.3% | $15.8M-11.9% | $17.9M+24.8% | $14.3M+70.5% | $8.4M+19.3% | $7.0M+45.6% | $4.8M+67.9% | $2.9M-3.1% | $3.0M |
| SG&A Expenses | $255.1M | $266.2M+18.3% | $225.1M+6.6% | $211.1M+1.2% | $208.7M+7.1% | $194.8M+7.6% | $181.0M-8.7% | $198.2M-23.3% | $258.5M+17.4% | $220.1M+26.9% | $173.4M+30.0% | $133.4M+47.4% | $90.5M+95.7% | $46.2M+136.0% | $19.6M+99.0% | $9.8M |
| Operating Income | $8.8M | $63.9M+8.5% | $58.9M+58.6% | $37.1M+352.0% | -$14.7M-108.9% | -$7.1M+84.5% | -$45.4M-114.5% | -$21.2M-439.2% | -$3.9M-108.5% | $46.2M+5128.8% | $884K-96.4% | $24.4M+243.2% | $7.1M+369.0% | -$2.6M+50.7% | -$5.4M+45.1% | -$9.8M |
| Interest Expense | N/A | $1.8M-54.7% | $3.9M-40.1% | $6.6M+30.2% | $5.0M+201.4% | -$5.0M+37.3% | -$7.9M-68.7% | -$4.7M-993.4% | $527K+705.7% | -$87K-125.7% | $339K+294.2% | $86K+79.2% | $48K+6.7% | $45K-92.4% | $593K+403.3% | $118K |
| Income Tax | $5.3M | $17.7M+15.6% | $15.3M+141.6% | -$36.8M-17967.0% | $206K-16.6% | $247K+102.0% | -$12.3M-245080.0% | -$5K-100.0% | $26.6M+235.4% | -$19.6M-12770.3% | $155K+103.0% | -$5.2M-721.2% | $832K+732.0% | $100K | $0 | $0 |
| Net Income | $6.2M | $48.6M+14.5% | $42.4M-27.2% | $58.2M+292.8% | -$30.2M-193.6% | -$10.3M+79.1% | -$49.3M-92.7% | -$25.6M+14.7% | -$30.0M-146.3% | $64.7M+16496.7% | $390K-98.7% | $29.4M+373.4% | $6.2M+251.3% | -$4.1M+46.3% | -$7.7M+24.8% | -$10.2M |
| EPS (Diluted) | — | $0.32+14.3% | $0.28-24.3% | $0.37 | -$0.33-120.0% | -$0.15+80.5% | -$0.77 | -$0.24+14.3% | -$0.28-150.0% | $0.56 | $0.00-100.0% | $0.26+420.0% | $0.05+225.0% | -$0.04+55.6% | -$0.09 | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MDXG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $342.7M+29.8% | $263.9M+10.4% | $239.0M+39.4% | $171.4M-8.8% | $187.9M-7.0% | $202.0M+20.9% | $167.2M+36.1% | $122.8M+1.3% | $121.3M+3.4% | $117.3M-13.7% | $135.9M+24.4% | $109.3M+29.0% | $84.7M+140.7% | $35.2M+29.8% | $27.1M |
| Current Assets | $277.5M+44.6% | $191.9M+16.8% | $164.3M+22.4% | $134.2M-9.6% | $148.5M-7.5% | $160.6M+30.3% | $123.2M+66.4% | $74.0M+51.9% | $48.7M-18.0% | $59.5M-38.2% | $96.3M+12.4% | $85.7M+31.0% | $65.4M+261.5% | $18.1M+162.9% | $6.9M |
| Cash & Equivalents | $166.1M+59.1% | $104.4M+27.3% | $82.0M+24.3% | $66.0M-24.3% | $87.1M-9.1% | $95.8M+38.7% | $69.1M+53.1% | $45.1M+64.2% | $27.5M-9.4% | $30.3M+15.3% | $26.3M-43.5% | $46.6M+5.7% | $44.1M+552.6% | $6.8M+64.2% | $4.1M |
| Inventory | $25.3M+6.4% | $23.8M+13.3% | $21.0M+59.5% | $13.2M+15.8% | $11.4M+9.9% | $10.4M+13.8% | $9.1M-43.1% | $16.0M+68.9% | $9.5M-40.4% | $15.9M+112.8% | $7.5M+45.3% | $5.1M+32.3% | $3.9M+28.4% | $3.0M+324.2% | $713K |
| Accounts Receivable | $75.7M+35.6% | $55.8M+3.6% | $53.9M+25.0% | $43.1M+6.8% | $40.4M+13.9% | $35.4M+9.6% | $32.3M | $0-100.0% | $64.8M+3262.7% | $1.9M-96.4% | $53.8M+101.5% | $26.7M+65.7% | $16.1M+110.3% | $7.7M+304.5% | $1.9M |
| Goodwill | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M0.0% | $19.4M-2.7% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M-1.1% | $20.2M+400.1% | $4.0M0.0% | $4.0M0.0% | $4.0M0.0% | $4.0M0.0% | $4.0M |
| Total Liabilities | $86.1M+21.6% | $70.8M-26.5% | $96.3M-49.1% | $189.4M+0.8% | $187.8M-7.1% | $202.2M+52.3% | $132.8M+81.4% | $73.2M+54.2% | $47.5M-31.4% | $69.2M-31.6% | $101.2M+407.7% | $19.9M+79.1% | $11.1M-26.7% | $15.2M-0.2% | $15.2M |
| Current Liabilities | $64.3M+40.9% | $45.6M-0.9% | $46.0M+5.6% | $43.6M+2.8% | $42.4M-28.4% | $59.2M-12.1% | $67.3M-5.9% | $71.5M+56.2% | $45.8M-24.6% | $60.8M+127.0% | $26.8M+45.5% | $18.4M+91.5% | $9.6M+91.5% | $5.0M+6.0% | $4.7M |
| Long-Term Debt | $16.5M-7.6% | $17.8M-62.9% | $48.1M-1.0% | $48.6M+1.0% | $48.1M+0.9% | $47.7M-23.0% | $61.9M | $0 | N/A | N/A | N/A | N/A | $0-100.0% | $4.0M+46.2% | $2.7M |
| Total Equity | $256.5M+32.9% | $193.1M+35.3% | $142.7M+893.4% | -$18.0M-22036.6% | $82K+154.7% | -$150K-100.4% | $34.4M-30.7% | $49.7M-32.7% | $73.8M+53.5% | $48.1M+38.4% | $34.7M-61.1% | $89.3M+21.4% | $73.6M+267.7% | $20.0M+68.2% | $11.9M |
| Retained Earnings | -$42.7M+53.2% | -$91.3M+31.7% | -$133.7M+30.3% | -$191.9M-18.7% | -$161.7M-6.8% | -$151.4M-48.3% | -$102.1M-33.4% | -$76.6M-64.4% | -$46.6M+58.2% | -$111.3M-191.9% | -$38.1M+43.6% | -$67.6M+8.4% | -$73.8M-5.9% | -$69.7M-12.4% | -$62.0M |
MDXG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $46.1M | $74.0M+11.8% | $66.2M+147.2% | $26.8M+249.6% | -$17.9M-802.8% | -$2.0M+93.5% | -$30.3M+23.2% | -$39.4M-210.1% | $35.8M-43.1% | $62.9M+163.9% | $23.8M+26.8% | $18.8M+11.9% | $16.8M+6016.2% | -$284K+91.5% | -$3.3M+50.0% | -$6.7M |
| Capital Expenditures | N/A | N/A | N/A | $2.0M+31.2% | $1.5M-53.0% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | $24.8M+227.7% | -$19.4M-273.2% | -$5.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$11.9M | -$6.9M+28.1% | -$9.6M-344.7% | -$2.2M+19.0% | -$2.7M+21.6% | -$3.4M+25.5% | -$4.6M-1003.8% | $504K+105.5% | -$9.2M-70.8% | -$5.4M+53.8% | -$11.7M-1622.4% | -$678K+94.4% | -$12.2M-301.6% | -$3.0M-375.0% | -$637K+9.3% | -$703K |
| Financing Cash Flow | -$17.3M | -$5.4M+84.2% | -$34.2M-299.1% | -$8.6M-1377.6% | -$580K+82.7% | -$3.4M-105.4% | $61.6M-2.1% | $62.9M+803.6% | -$8.9M+85.2% | -$60.4M-640.9% | -$8.2M+77.5% | -$36.2M-1588.0% | -$2.1M-105.3% | $40.6M+514.7% | $6.6M-34.8% | $10.1M |
| Share Buybacks | N/A | $0 | $0-100.0% | $9.5M | $0 | $0-100.0% | $900K | $0-100.0% | $7.6M-88.9% | $68.3M+556.7% | $10.4M-74.1% | $40.1M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MDXG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.6%-0.2pp | 82.8%-0.2pp | 83.0%+1.0pp | 82.0%-1.7pp | 83.6%-0.5pp | 84.2%-1.4pp | 85.6%-4.3pp | 89.9%+0.8pp | 89.0%+3.0pp | 86.1%-3.2pp | 89.2%-0.1pp | 89.3%+5.0pp | 84.2%+3.4pp | 80.8%+24.1pp | 56.7% |
| Operating Margin | 15.3%-1.6pp | 16.9%+5.3pp | 11.6%+17.1pp | -5.5%-2.6pp | -2.9%+15.4pp | -18.3%-11.2pp | -7.1%-6.0pp | -1.1%-15.5pp | 14.4%+14.0pp | 0.4%-12.6pp | 13.0%+7.0pp | 6.0%+10.5pp | -4.5%+15.3pp | -19.8% | -125.8% |
| Net Margin | 11.6%-0.6pp | 12.2%-6.0pp | 18.1%+29.4pp | -11.3%-7.0pp | -4.3%+15.6pp | -19.9%-11.3pp | -8.6%-0.2pp | -8.3%-28.5pp | 20.2%+20.0pp | 0.2%-15.5pp | 15.7%+10.5pp | 5.3%+12.2pp | -7.0%+21.4pp | -28.3% | -131.4% |
| Return on Equity | 18.9%-3.0pp | 22.0%-18.8pp | 40.8% | N/A | -12542.7% | N/A | -74.4%-14.0pp | -60.4%-148.1pp | 87.7%+86.9pp | 0.8%-84.0pp | 84.8%+77.8pp | 7.0%+12.6pp | -5.6%+32.7pp | -38.3%+47.4pp | -85.7% |
| Return on Assets | 14.2%-1.9pp | 16.1%-8.3pp | 24.4%+42.0pp | -17.6%-12.1pp | -5.5%+18.9pp | -24.4%-9.1pp | -15.3%+9.1pp | -24.4%-77.8pp | 53.4%+53.1pp | 0.3%-21.3pp | 21.7%+16.0pp | 5.7%+10.5pp | -4.9%+16.9pp | -21.8%+15.8pp | -37.6% |
| Current Ratio | 4.32+0.1x | 4.21+0.6x | 3.57+0.5x | 3.08-0.4x | 3.51+0.8x | 2.71+0.9x | 1.83+0.8x | 1.030.0x | 1.06+0.1x | 0.98-2.6x | 3.60-1.1x | 4.66-2.2x | 6.81+3.2x | 3.61+2.2x | 1.45 |
| Debt-to-Equity | 0.060.0x | 0.09-0.2x | 0.34 | N/A | 586.91 | N/A | 1.80+1.8x | 0.00-0.6x | 0.64-0.8x | 1.44-1.5x | 2.91+2.7x | 0.22+0.2x | 0.00-0.2x | 0.200.0x | 0.23 |
| FCF Margin | N/A | N/A | 7.7%+15.0pp | -7.2%-5.1pp | -2.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Mimedx Group Inc Ranks
Frequently Asked Questions
What is Mimedx Group Inc's annual revenue?
Mimedx Group Inc (MDXG) reported $418.6M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mimedx Group Inc's revenue growing?
Mimedx Group Inc (MDXG) revenue grew by 20.0% year-over-year, from $348.9M to $418.6M in fiscal year 2025.
Is Mimedx Group Inc profitable?
Yes, Mimedx Group Inc (MDXG) reported a net income of $48.6M in fiscal year 2025, with a net profit margin of 11.6%.
What is Mimedx Group Inc's EBITDA?
Mimedx Group Inc (MDXG) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Mimedx Group Inc have?
As of fiscal year 2025, Mimedx Group Inc (MDXG) had $166.1M in cash and equivalents against $16.5M in long-term debt.
What is Mimedx Group Inc's gross margin?
Mimedx Group Inc (MDXG) had a gross margin of 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mimedx Group Inc's operating margin?
Mimedx Group Inc (MDXG) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Mimedx Group Inc's net profit margin?
Mimedx Group Inc (MDXG) had a net profit margin of 11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Mimedx Group Inc's return on equity (ROE)?
Mimedx Group Inc (MDXG) has a return on equity of 18.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mimedx Group Inc's operating cash flow?
Mimedx Group Inc (MDXG) generated $74.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Mimedx Group Inc's total assets?
Mimedx Group Inc (MDXG) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Mimedx Group Inc spend on research and development?
Mimedx Group Inc (MDXG) invested $15.1M in research and development during fiscal year 2025.
What is Mimedx Group Inc's current ratio?
Mimedx Group Inc (MDXG) had a current ratio of 4.32 as of fiscal year 2025, which is generally considered healthy.
What is Mimedx Group Inc's debt-to-equity ratio?
Mimedx Group Inc (MDXG) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mimedx Group Inc's return on assets (ROA)?
Mimedx Group Inc (MDXG) had a return on assets of 14.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mimedx Group Inc's Altman Z-Score?
Mimedx Group Inc (MDXG) has an Altman Z-Score of 6.81, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mimedx Group Inc's Piotroski F-Score?
Mimedx Group Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mimedx Group Inc's earnings high quality?
Mimedx Group Inc (MDXG) has an earnings quality ratio of 1.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mimedx Group Inc cover its interest payments?
Mimedx Group Inc (MDXG) has an interest coverage ratio of 35.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mimedx Group Inc?
Mimedx Group Inc (MDXG) scores 76 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.